Evaluation of Clinicopathological Factors in PD-1 Response: Derivation and Validation of a Prediction Scale for Response to PD-1 Monotherapy

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2017.70
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PD-L1 and BCG Response Prediction

Nature Reviews Urology
Urology
2019English

The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response

Klinicka Onkologie
Oncology
2016English

PD-1 Blockade in GBM: Uncovering Response Clues

Cancer Discovery
Oncology
2019English

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Bi-Centric Cohort Study

Targeted Oncology
Cancer ResearchOncologyPharmacology
2019English

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2017English

Complete Response to Anti-Pd-1 Antibody Monotherapy in Metastatic Melanoma-Can Therapy Be Discontinued? A Review of Current Literature

Journal of Cancer Biology and Therapeutics
2019English

Blood Monocyte Frequency May Be a Biomarker for Response to Anti–PD-1

Cancer Discovery
Oncology
2018English

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy